# Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea

> **NCT02137629** · — · COMPLETED · sponsor: **Celgene** · enrollment: 511 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Vidaza®

## Key facts

- **NCT ID:** NCT02137629
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-27
- **Primary completion:** 2016-05-19
- **Final completion:** 2016-05-19
- **Target enrollment:** 511 (ACTUAL)
- **Last updated:** 2019-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02137629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02137629, "Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02137629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*